REGENERON PHARMACEUTICALS, INC. (REGN): what the price assumes

In the published model solve dated 2026-Q2, anchored at $797.00, REGENERON PHARMACEUTICALS, INC. (REGN) is priced for +10.8% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-03.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/REGN

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.3% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

At $610.05 (as of June 27, 2026), Regeneron is supported by asset-based, relative-multiple, and growth-DCF value, with the methods describing a value-and-asset name rather than a pure growth bet. The implied growth baked into the price is a modest 6 percent, low for a company whose two biggest drugs are still expanding.

The near-term debate is the Eylea franchise. Combined U.S. Eylea sales fell 10 percent under biosimilar and competitive pressure, even as the new Eylea HD formulation grew 52 percent. The franchise is shrinking and reinventing itself at the same time.

The offset is breadth. Dupixent, recorded by partner Sanofi, grew 33 percent to $4.9 billion globally, Libtayo grew 54 percent, and the pipeline added a first gene-therapy approval. With a fortress balance sheet and a fresh $3 billion buyback, the question is whether the growers outrun the eroders.

Bull Case

Start with the risk the bears lead on, because it is real: the Eylea franchise is under attack. Regeneron's own filings warn of biosimilar competition in the United States, including additional aflibercept biosimilars expected to launch and Amgen's Pavblu, which entered the market in late 2024 (FY2025 10-K, accession 0000872589-26-000008). Combined U.S. Eylea and Eylea HD net sales fell 10 percent to $941 million in the first quarter of 2026 on lower legacy-Eylea volume. For a drug that was once the company's anchor, that is a genuine erosion, and any honest bull case has to begin by conceding it.

Now look at whether the data actually supports the fear or undermines it. The same quarter showed Eylea HD, the longer-duration successor formulation, growing 52 percent to $468 million, meaning Regeneron is migrating its own patients to a product biosimilars cannot copy. More importantly, the company is no longer an Eylea story. Total revenue rose 19 percent to $3.6 billion. Dupixent, the immunology blockbuster Regeneron developed with Sanofi, grew 33 percent to $4.9 billion in global net sales and is still building volume across five indications, with the COPD launch drawing the sharpest physician interest. Libtayo in oncology grew 54 percent to $438 million. The fear is concentrated in one aging franchise; the growth is spread across several younger ones.

The valuation and the balance sheet seal the case. The methods cluster around and above the price: the DCF perpetual-growth model lands near $854, relative valuation near $808, and the DCF exit-multiple near $684, while the asset and earnings methods land in the $440 to $560 range, so the blend sits right at the $610 price. Regeneron earns a 24 percent operating margin, carries a fortress balance sheet, and just authorized a fresh $3 billion buyback, signaling management views the stock as cheap. With analysts carrying a Buy consensus and price targets clustered in the $750 to $875 range, the bull thesis is that the market is pricing only 6 percent implied growth into a company whose pipeline and immunology franchise can deliver more, while the Eylea decline is already in the numbers.

Bear Case

The structural feature that should give a holder pause is hidden in the revenue mix: more than half of Regeneron's revenue is collaboration revenue, not product Regeneron sells itself. Dupixent, the single fastest-growing and largest contributor to the franchise's momentum, is recorded by Sanofi, and Regeneron books its share of profits through the collaboration. That arrangement is lucrative, but it is also a dependence: Regeneron does not control Dupixent's commercialization, pricing, or the cost structure behind it, and the company raised its 2026 cost-of-collaboration guidance to $955 million to $1.035 billion while cutting product gross-margin guidance to 77 to 78 percent from 79 to 80 percent. A balance sheet and income statement built on a partner's drug is strong until the economics of that partnership shift, and the margin guidance moving the wrong way is the first sign of cost headwinds the company only partly controls.

The second risk is the one the bull case concedes but cannot dismiss: the Eylea cliff is structural, not cyclical. Biosimilar aflibercept is launching from multiple sponsors, Amgen's Pavblu is already in the U.S. market, and additional versions are expected (FY2025 10-K, accession 0000872589-26-000008). Eylea HD is the defense, but converting an entire installed base to a higher-priced successor while biosimilars undercut the legacy product is a race against price erosion and payer pressure. Combined U.S. Eylea sales already fell 10 percent. If Eylea HD adoption slows or payers push back on its premium, a franchise that still contributes meaningfully to product sales keeps shrinking faster than HD can backfill.

Third, the price already embeds the optimistic read. Regeneron trades near $610 with the growth and relative lenses valuing it near or slightly above the quote, so the stock is roughly fairly priced on most frames, not cheap. GAAP net income actually fell 10 percent in the first quarter even as revenue grew, a reminder that mix and cost pressures are compressing the bottom line. Pipeline-dependent biotech valuations are unforgiving: a single Phase 3 failure, an FDA setback, or a competitive readout against fianlimab or Libtayo in oncology would force the growth-DCF and relative methods that hold the price up to reset lower. The bear case is not that Regeneron is a bad company; it is that the price assumes the new drugs win and the old ones decline gracefully, and biology does not always cooperate.

Valuation

Regeneron is valued as a profitable, mature biotech, and at $610.05 the methods describe a company that is roughly fairly priced rather than obviously cheap or expensive. The price is supported by asset-based, relative-multiple, and growth-DCF value simultaneously, which the priced-in read characterizes as a value-and-asset-supported name, not a pure growth bet. The implied growth embedded in the price is only about 6 percent, modest for a company with a 24 percent operating margin and several still-expanding franchises.

The methods bracket the price from both sides. The forward and relative lenses land above it: the DCF perpetual-growth near $854, relative valuation near $808, and EV/EBITDA relative near $566. The asset and earnings lenses land below: earnings-power value near $458, two-stage excess return near $542, residual income near $560, and the FCF-yield methods in the $322 to $422 range, reflecting that free cash flow runs lighter than reported earnings. The blended X-ray central estimate sits near $613, essentially on top of the $610 price.

The 6 percent implied growth is the key number to weigh; if Dupixent, Libtayo, and the pipeline can beat it, the stock is undervalued, and if Eylea erodes faster than HD backfills, the conservative methods near $450 to $560 set the floor.

Catalysts

First-quarter 2026 results, reported in late April, beat on the top line with total revenue up 19 percent to $3.605 billion. Non-GAAP net income rose 12 percent to about $1.04 billion, though GAAP net income fell 10 percent to $727 million on mix and cost pressures. Dupixent global net sales, recorded by Sanofi, rose 33 percent to $4.9 billion; Libtayo rose 54 percent to $438 million; Eylea HD U.S. sales jumped 52 percent to $468 million, while combined U.S. Eylea and Eylea HD sales fell 10 percent to $941 million under competitive pressure. Management cut full-year product gross-margin guidance to 77 to 78 percent and raised collaboration cost guidance, and authorized a fresh $3 billion share buyback.

The pipeline delivered a milestone with Regeneron's first gene-therapy approval in the quarter. The most-watched commercial catalyst is the Dupixent COPD launch, one of five indications still building volume and drawing the sharpest physician interest, alongside oncology progress with fianlimab and Libtayo.

Near-term catalysts to watch: the pace of Eylea HD conversion against new aflibercept biosimilars, Dupixent COPD uptake, oncology pipeline readouts including fianlimab, any further changes to margin guidance, and the cadence of the buyback. Analyst sentiment is a Buy consensus with price targets clustered around $750 to $875, and Bank of America recently turned more constructive citing a better view on Eylea HD and 2026 catalysts.

Peer Cohorts (Per Segment, With Filing Citations)

Regeneron (single reportable segment) (reported)

• VRTX (VERTEX PHARMACEUTICALS INC / MA)
• FY2025 10-K: 19319 10.20 Form of Restricted Stock Unit Agreement Under 2013 Stock and Option Plan.* 10-K (Exhibit 10.17) February 13, 2020 000-19319 10.21 Form of Restricted Stock Unit Agreement under 2013 Stock and Option Plan (granted on or after January 1, 2025).* 10-K (Exhibit 10.21) February 13, 2025 000-19319 10.22 Form of…
• FY2025 10-K: …the Sarbanes- Oxley Act of 2002. X 32.1 Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002. X Clawback Policy 97.1 Policy Relating to Recovery of Erroneously Awarded Compensation 10-K (Exhibit 97.1) February 15, 2024 000-19319 69 Exhibit…
• BMRN (BioMarin Pharmaceutical Inc)
• FY2025 10-K: …results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled "Forward-Looking Statements" that appears at the beginning of this Annual Report on Form 10-K. These…
• FY2025 10-K: 2006 and as amended and restated on April 16, 2015, previously filed with the SEC on June 15, 2015 as Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. 10.4† Form of Agreement Regarding Restricted Share Units for the BioMarin Pharmaceutical Inc.…
• ALNY (ALNYLAM PHARMACEUTICALS, INC.)
• FY2025 10-K: …Agreement, which terminated the C5 Co-Co Collaboration Agreement and granted Regeneron a worldwide license to cemdisiran as a monotherapy in addition to the license to cemdisiran in combination with anti-C5 antibodies. Through the Amended C5 License Agreement, Regeneron is now solely responsible for development,…
• FY2025 10-K: …The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a co-co collaboration agreement covering the continued development of cemdisiran, our C5 siRNA, currently in development…
• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …in consolidation. Certain reclassifications have been made to previously reported amounts to conform to the current period presentation. Revenue Recognition We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in…
• FY2025 10-K: …false 2025 FY 0000914475 P3Y http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent 0.7 - P3Y P3Y one one one one iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure nbix:non-clinicalStageCompound nbix:preclinicalCandidate nbix:undisclosedProgram nbix:geneTherapyProgram nbix:segment 0000914475 2025-01-01…
• EXEL (EXELIXIS, INC.)
• FY2025 10-K: .S. for previously treated advanced RCC to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters in a global pivotal trial: overall survival (OS); progression-free survival (PFS); and objective response rate (ORR). To date, CABOMETYX remains the only single-agent…
• FY2025 10-K: Results of Operations" are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company's or our industry's results, levels…
• AMGN (Amgen Inc.)
• FY2025 10-K: …antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen's sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payers and PBMs have harmed the sales of its product PRALUENT ® and focuses on two primary…
• FY2025 10-K: Regeneron in the BPCIA exchange (the 2024 Complaint). The lawsuit stems from Amgen's submission of an application under the BPCIA for FDA licensure of F-54 PAVBLU as biosimilar to Regeneron's EYLEA ® . By its complaint, Regeneron seeks, among other remedies, an injunction prohibiting the commercial manufacture, use,…
• GILD (GILEAD SCIENCES, INC.)
• FY2025 10-K: , Asegua Therapeutics LLC ("Asegua"). In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region. We have one operating segment which primarily focuses on the…
• FY2025 10-K: …product; the probability of technical and regulatory success; the time and resources needed to complete the development and approval of SG in NSCLC; an appropriate discount rate based on the estimated weighted-average cost of capital for companies with profiles similar to our profile; and risks related to the…
• BIIB (BIOGEN INC.)
• FY2025 10-K: …to sublease the property. For additional information on our acquisition of Reata, please read Note 2, Acquisitions , to these consolidated financial statements. Restructuring Reserve Charges and spending related to workforce reductions are summarized as follows: (In millions) Workforce Reductions Restructuring…
• FY2025 10-K: …using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from 6.2 % to 7.0 %, and probabilities of technological and regulatory success ranging from 67.0 % to near-certain probability. Of the total contingent consideration recorded as of the transaction close date,…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.